BofA raised the firm’s price target on Regeneron (REGN) to $575 from $565 and keeps an Underperform rating on the shares. Q4 results were “good,” but FY25 guidance was “not very useful” as guidance was provided for only expenses as usual, which is “not very helpful when pondering the negative impact biosimilar Eylea,” namely Amgen’s (AMGN) Pavblu, might have, the analyst tells investors. In the nearer-term, the firm thinks consensus EPS could be at risk from faster-than-expected Eylea erosion, the analyst added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REGN:
- Regeneron price target lowered to $759 from $940 at Baird
- Regeneron upgraded to Outperform from Market Perform at Leerink
- Regeneron Reports Strong 2024 Earnings and Strategic Initiatives
- Regeneron Reports Strong Growth and Promising Pipeline
- China retaliates with tariffs on U.S., Merck falls after earnings: Morning Buzz